Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1532426

Cover Image

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1532426

Rnai Technology Market, By Application, By End User, By Geography

PUBLISHED:
PAGES: 165 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4500
PDF (Multi User License)
USD 7000
PDF (Enterprise User License)
USD 10000

Add to Cart

Global RNAi technology market is estimated to be valued at USD 2.70 Bn in 2024 and is expected to reach USD 7.10 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 14.8% from 2024 to 2031.

Report Coverage Report Details
Base Year: 2023 Market Size in 2024: US$ 2.70 Bn
Historical Data for: 2019 to 2023 Forecast Period: 2024 to 2031
Forecast Period 2024 to 2031 CAGR: 14.80% 2031 Value Projection: US$ 7.10 Bn
Figure. RNAi technology market Share (%), By Region 2024
Rnai Technology Market - IMG1

Global RNAi technology market growth is driven by growing applications of RNA interference technology in therapeutics development and research. RNA interference or RNAi refers to the process of gene silencing mediated by short interfering RNAs (siRNAs) or microRNAs (miRNAs). It has emerged as a powerful tool for selective inhibition of gene expression and functional genomics screens. RNAi holds immense potential for developing novel therapeutics by silencing specific disease-causing genes. The development of safe and effective delivery systems further contributes to the commercialization of RNAi-based therapies. Significant investments in RNAi research and development from biopharma companies and government organizations are resulting in a strong product pipeline.

Market Dynamics:

Global RNAi technology market growth is driven by increasing applications of RNAi technology for developing treatments across therapeutic areas. Several drug candidates targeting metabolic, cardiovascular and neurodegenerative disorders are currently under clinical trials. The strong product pipeline and entry of novel RNAi drugs are creating high optimism around the therapeutic potential of this technology. However, technical challenges in RNAi delivery and off-target effects can hamper the market growth. Moreover, requirement of high capital investments for building R&D infrastructure and clinical development deters many small companies. Ongoing research on overcoming the delivery challenges through novel delivery systems such as lipid nanoparticles, polymeric nanoparticles and ligand-conjugated molecules can offer market growth opportunities. Promising clinical outcomes of RNAi-based drugs in late-stage trials can offer market growth opportunities.

Key Features of the Study:

  • This report provides in-depth analysis of the global RNAi technology market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global RNAi technology market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals, Mirna Therapeutics, and Quark Pharmaceuticals
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global RNAi technology market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global RNAi technology market

Detailed Segmentation-

  • By Application
    • Drug Discovery and Development
    • Therapeutics
    • Neurology
    • Oncology
    • Infectious Diseases
    • Metabolic Diseases
    • Others
    • Functional Genomics
    • Other
  • By End User
    • Pharmaceutical & Biotechnology Companies
    • Academic & Research Institutes
    • CROs & CMOs
    • Others
  • By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • Alnylam Pharmaceuticals
    • OriGene Technologies, Inc.
    • Arrowhead Pharmaceuticals
    • Dicerna Pharmaceuticals
    • Silence Therapeutics
    • Ionis Pharmaceuticals
    • Merck & Co.
    • Qiagen N.V.
    • Thermo Fisher Scientific
    • Synlogic
    • Benitec Biopharma
    • Gradalis
    • Sirnaomics, Inc.
    • Marina Biotech
    • Quark Pharmaceuticals
    • Regulus Therapeutics
    • GeneCare Research Institute Co., Ltd.
    • ASC Therapeutics
Product Code: CMI5281

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Application
    • Market Snapshot, By End User
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Regulatory Scenario
  • Acquisitions and Partnerships Scenario
  • Funding and Investments
  • PEST Analysis
  • Porter's Analysis

4. Global Rnai Technology Market - Impact of Coronavirus (COVID-19) Pandemic

  • Overall Impact
  • Government Initiatives
  • COVID-19 Impact on the Market

5. Global RNAi Technology Market, By Application, 2019 - 2031, (USD Bn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2019 - 2031
    • Segment Trends
  • Drug Discovery and Development
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Therapeutics
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Neurology
  • Oncology
  • Infectious Diseases
  • Metabolic Diseases
  • Others
  • Functional Genomics
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global RNAi Technology Market, By End User, 2019 - 2031, (USD Bn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2019 - 2031
    • Segment Trends
  • Pharmaceutical & Biotechnology Companies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Academic & Research Institutes
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • CROs & CMOs
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global RNAi Technology Market, By Region, 2019 - 2031, (USD Bn)

  • Introduction
    • Market Share Analysis, By Region, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, For Region, 2019-2031
    • Regional Trends
      • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
      • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
    • Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
      • North Africa
      • Central Africa
      • South Africa

8. Competitive Landscape

  • Company Profiles
    • Alnylam Pharmaceuticals
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • OriGene Technologies, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Arrowhead Pharmaceuticals
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Dicerna Pharmaceuticals
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Silence Therapeutics
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Ionis Pharmaceuticals
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Merck & Co.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Qiagen N.V.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Thermo Fisher Scientific
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Synlogic
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Benitec Biopharma
    • Gradalis
    • Sirnaomics, Inc.
    • Marina Biotech
    • Quark Pharmaceuticals
    • Regulus Therapeutics
    • GeneCare Research Institute Co., Ltd.
    • ASC Therapeutics

9. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

10. References and Research Methodology

  • References
  • Research Methodology
  • About Us and Sales Contact
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!